Start of Phase 1/2 clinical trial for IPH6401/SAR'514 sponsored by Sanofi

Exclusive license of antibodies to Takeda for celiac disease research program

Sanofi gains exclusive license to Innate’s B7H3 ANKET® program and options for two additional targets

Start of Phase 1/2 clinical trial for IPH6101/SAR'579 sponsored by Sanofi

First Innate asset progressing to Phase 3 - monalizumab partnered with AstraZeneca

Listing on the Nasdaq

Multi-term agreement with AstraZeneca

Selection of IPH5201 as development candidate

Clinical trial collaboration with AstraZeneca on avdoralimab (IPH5401)

Eric Vivier appointed Chief Scientific Officer

Acquisition of anti-C5aR (IPH5401 now avdoralimab) from Novo Nordisk A/S

Key leadership and corporate governance changes: Mondher Mahjoubi appointed Chief Executive Officer and Chairman of the Executive Board ; Hervé Brailly, co-founder of the Company appointed Chairman of the Supervisory Board

New CD73 checkpoint inhibitor program (IPH53)

Research collaboration and licensing agreement on NK cell engagers with Sanofi

Co-development and commercialization agreement with AstraZeneca on monalizumab

Start of Phase 1 trial for lacutamab (IPH4102)

Collaboration and licensing agreement with Bristol-Myers Squibb on lirilumab

Initiation of Phase 1 clinical trials with IPH2201 (monalizumab) by Novo Nordisk A/S

Enlarging of the collaboration and licensing agreement with Novo Nordisk A/S

Initial Public Offering (“IPO”) on the NYSE-Euronext Paris

First collaboration and licensing deal with Novo Nordisk A/S for the development of an anti-KIR antibody program, potentiating NK cells activation against tumors

Company inception


Innate Pharma was founded in 1999 by a group of immunologists, four European Scientists - pioneers in the field of innate immunity (Alessandro Moretta, Marc Bonneville, Jean-Jacques Fournié and Eric Vivier) - and two managers from the biopharmaceutical industry (Hervé Brailly and François Romagné).

Innate founders

From left to right:

Hervé BRAILLY, PhD, Chairman of the Supervisory Board of Innate Pharma since January 2017, former Chairman of the Executive Board.

Eric VIVIER, DVM, PhD, is a Professor at Aix-Marseille University and member of the Institut Universitaire de France. He has been appointed Chief Scientific Officer of the Company in January 2018. He is Head of the "NK" research group at the Centre d'Immunologie de Marseille Luminy (CIML), France and has also been Director of the Centre between 2008 and 2017. Eric Vivier is co-founder and coordinator of the University-Hospital Federation Marseille-Immunopôle.

Marc BONNEVILLE, DVM, PhD, joined the Institut Mérieux in 2013 as Vice President of Medical and Scientific Affairs. He previously was a Research Director at CNRS and a Director of Immunology Institute INSERM 643 in Nantes, France.

The late lamented Alessandro MORETTA, MD, PhD, was Professor of Experimental Medicine at Genoa University, Italy. He was laureate of the 2011 Yvette Mayent European prize for his scientific contributions to cancer immunology.

Jean-Jacques FOURNIÉ, PhD, is Director of CRCT (The Cancer Research Center of Toulouse). He is a Research Director at CNRS and previously was a Director of the research group "Non-Conventional Antigens" at INSERM 395 in Toulouse, France.

François ROMAGNÉ, PhD, CSO of Innate Pharma from its inception until the end of 2013. He is now the Scientific Director of Mi-mAbs, the new immunotechnology platform at Aix-Marseille University and Professor of immunotechnology at Aix-Marseille University.